...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Epigenetic BET-inhibition to combat COVID-19
CALGARY, Alberta, March 24, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown apabetalone to inhibit specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from interacting with a SARS-CoV-2 viral protein, with potential for limiting viral reproduction in human cells.
The article titled: “A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing” by Gordon et al, identified BRD2/4 as a binding partner of viral protein E. Apabetalone was shown to disrupt this interaction. A paragraph in the publication states the following about Bromodomain proteins:
SARS-CoV-2 envelope interacts with bromodomain proteins
Surprisingly, we find that the transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4, potentially disrupting BRD-histone binding by mimicking histone structure. BRD2 is a member of the bromodomain and extra-terminal (BET) domain family whose members bind acetylated histones to regulate gene transcription. The N-terminus of histone 2A shares local sequence similarity over an alpha-helix of approximately 15 residues, some of which are in a transmembrane segment, of Protein E (Gordon et al., 2020, p.7).
“This novel research is certainly very encouraging and warrants additional testing of apabetalone, our investigational phase 3 clinical candidate with safety data in more than 4,000 subjects,” said Donald McCaffrey, President and CEO of Resverlogix. “Harnessing epigenetic modulation may be a potent tool in slowing down COVID-19 virus spread and disease severity, and as we announced yesterday, we would like to collaborate quickly with anyone who is testing drugs for COVID-19 in preclinical and clinical studies.”
Interested COVID-19 collaborators can contact:
Donald McCaffrey, President & CEO
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
Please login to post a reply